Imatinib use extended

The licence for Glivec (imatinib) has been extended to include the treatment of adult patients with: - newly diagnosed Philadelphia chromosome positive acute lymphoblastic leukaemia integrated with chemotherapy, or as monotherapy in patients with relapsed or refractory disease. - unresectable dermatofibrosarcoma protuberans or patients with recurrent and/or metastatic disease who are not eligible for surgery.

Want news like this straight to your inbox?
Sign up for our bulletins

Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

More from MIMS

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

Reduce insulin doses carefully when starting GLP-1 agonists, MHRA advises

A careful stepwise approach is needed when reducing...

Prescribers advised not to use newer anticoagulants in patients with antiphospholipid syndrome
Drug shortages - live tracker

Drug shortages - live tracker

Check on the latest drug supply issues with MIMS' shortages...

Novel MS drug gains NICE approval

Novel MS drug gains NICE approval

New NICE guidance recommends ocrelizumab (Ocrevus)...